Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 7
---
)            
 Diana Layfield (Non-Executive Director)       
 Anna Manz (Non-Executive Director)            
 Sherilyn McCoy (Non-Executive Director)       
 Tony Mok (Non-Executive Director)             
 Nazneen Rahman (Non-Executive Director)       
 Marcus Wallenberg (Non-Executive Director)    | ​ | ​ | AstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCambridgeUnited KingdomCB2 0AA | ​ |

29 September 2025 To all Shareholders including CSN Participants, and, for information only, to participants in the AstraZeneca Share Plans and persons with information rights Dear Shareholder On behalf of the Board, I am pleased to invite you to a digitally-enabled general meeting of AstraZeneca to be held on 3 November 2025 at 2:30 p.m. (GMT) to consider the proposal announced earlier today (the “General Meeting” ). This letter summarises the background to and reasons for the proposal, which entails a new Harmonised Listing Structure across the London Stock Exchange, Nasdaq Stockholm and the NYSE. This requires upgrading AstraZeneca’s existing US equity listing by way of a direct listing of AstraZeneca Shares on the NYSE, replacing the existing US listing of AstraZeneca ADSs on Nasdaq (the “Harmonised Listing Structure” ). This requires approval of certain amendments to the Company’s articles of association at the forthcoming General Meeting. AstraZeneca’s business has evolved considerably over the last decade, driven mainly by its successful record of innovation, which has in turn generated significant growth in Total Revenue and profitability. Total Revenue has increased from $24.7bn in 2015 to $54.1bn in 2024 and Core Operating Profit from $6.9bn to $16.9bn. Annual core R&D spending increased from $5.6bn to $12.2bn over the same period. A significant part of this growth has been generated from the expansion of the Company in the US, which as at year-end 2024 accounted for 43% of Total Revenue and is expected to represent 50% of our revenue by 2030. We have also enjoyed a notable expansion of our revenues in many geographies and we now have a very broad geographical footprint. The geographic composition of AstraZeneca’s investor base has also changed in the last decade, reflecting both AstraZeneca’s own business evolution as well as developments in the capital markets.